利伐沙班适应症

Rivaroxaban is a small molecule oral anticoagulant jointly developed by Bayer and Johnson & Johnson, with the trade name Xarelto. It obtained marketing approval in Canada and the European Union on September 15 and October 1, 2008 respectively. On July 1, 2011, the FDA approved the drug for the prevention of deep vein thrombosis in patients undergoing knee or hip replacement surgery. Its chemical name is: 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolin-5-yl)methyl)thiophene-2-carboxamide. What are the indications for rivaroxaban?

Rivaroxaban indications include: 1. For adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE). 2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. 3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

Rivaroxaban is an oral, bioavailable factor Xa inhibitor that selectively blocks the active site of factor Xa and does not require cofactors (such as antithrombin III) for activity. Factor X is activated into factor Xa (FXa) through endogenous and exogenous pathways, which plays an important role in the coagulation cascade.